You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 727 Topline safety and efficacy update of SUPLEXA-101, a first-in-human, single agent study of SUPLEXA therapeutic cells in 28 patients with metastatic solid tumours

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
727 Topline safety and efficacy update of SUPLEXA-101, a first-in-human, single agent study of SUPLEXA therapeutic cells in 28 patients with metastatic solid tumours

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Joshi R, Goh J, Gargosky S, et al
727 Topline safety and efficacy update of SUPLEXA-101, a first-in-human, single agent study of SUPLEXA therapeutic cells in 28 patients with metastatic solid tumours
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0727